The Arizona Senate has approved budget legislation that includes provisions to fund research into the medical potential of psilocybin mushrooms for a variety of conditions.
Rather than enact the reform through a standalone psychedelics bill that was introduced earlier this session, top lawmakers and the governor agreed to incorporate the proposal into appropriations measures, albeit at a lower funding level compared to the original measure.
The Senate passed an appropriations bill that calls for $5 million in funding for psilocybin research on Wednesday. A related health-focused budget measure that also cleared the chamber details requirements for the clinical trials that those dollars will support. The House has given initial approval to companion versions of the legislation, with final passage expected soon.
The original standalone psilocybin bill that unanimously cleared the House Military Affairs & Public Safety Committee in February would have appropriated $30 million for the studies over the course of three years.
Under the approved budget legislation, the state Department of Health Services (DHS) would distribute $5 million for fiscal year 2023-2024 for “whole mushroom psilocybin phase one, phase two and phase three clinical trials that are capable of being approved” by the federal Food and Drug Administration (FDA)
Read full article on Marijuana Moment